EC approves rilonacept

The European Commission approved rilonacept from Regeneron Pharmaceuticals Inc. (NASDAQ:RGEN) under exceptional circumstances to treat severe symptoms of Cryopyrin-Associated Periodic Syndromes (CAPS), including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). As part of the approval, Regeneron is required to annually submit new information to EMEA for review. Rilonacept is a recombinant protein with the heterodimeric IL-1 receptor linked to the Fc portion of human IgG. It is marketed in the U.S. as Arcalyst. Regeneron, which made the announcement after market close, was down $0.29 to $17.20 on Tuesday. ...